# Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age

> **NCT00379977** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 30 (—)

## Conditions studied

- Tetanus
- Haemophilus Influenzae Type b
- Acellular Pertussis
- Diphtheria

## Interventions

- **BIOLOGICAL:** diphtheria, tetanus, pertussis & Hib vaccine

## Key facts

- **NCT ID:** NCT00379977
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** 2006-12
- **Target enrollment:** 30 (—)
- **Last updated:** 2016-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00379977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00379977, "Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00379977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*